What is LOPJLB’s current signal on APGE?

LOPJLB’s latest quantitative signal on Apogee Therapeutics, Inc. (APGE) is BUY in a BULL regime. Signals are updated daily.

What market regime is APGE in?

Apogee Therapeutics, Inc. (APGE) is currently classified in the BULL HMM market regime on LOPJLB.

Apogee Therapeutics, Inc. (APGE)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$135.07-0.01%Close

BUYBULL · day 49

RANGE

DATA 2026-09-02

LOPJLB.COM

OHLCEMALEVELSSTOPFLIP52WSIGNALSBUYSELLEXHEXH ZONE

Key stats

Market cap: $8.4B
Beta: 0.34

P/E (TTM): -31.12

1W: +0.09%
1M: +0.66%

vs SPY 1W: -0.33%
vs SPY 1M: -1.40%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological…

Employees: 261
Headquarters: US
Founded: 2023
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 61.9M
Float: 92.4%

apogeetherapeutics.com ↗

Key executives

Michael Thomas Henderson — Chief Executive Officer & Director

Jane Pritchett V. Henderson — Chief Financial Officer

Carl Linden Dambkowski — Chief Medical Officer

SEC filings

EDGAR · CIK 19746400 · APGE

Analyst consensus

Hold

Bullish214.3%

Neutral1285.7%

Bearish00.0%

L $89.00Avg $130.92H $140.00

Target$130.92-3.07%

Last$135.07

FAQ

What is LOPJLB’s current signal on APGE?: LOPJLB’s latest quantitative signal on Apogee Therapeutics, Inc. (APGE) is BUY in a BULL regime. Signals are updated daily.
What market regime is APGE in?: Apogee Therapeutics, Inc. (APGE) is currently classified in the BULL HMM market regime on LOPJLB.
What does Apogee Therapeutics, Inc. (APGE) do?: Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life…

Key stats

Prediction markets

Company news

FAQ